A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group
Diana Loigom, Tobias S. S. Slørdahl, Anna Lysén, Agoston Gyula Szabo et autres
ee, no, dk, fr, gb, it, ie, us (code pays fourni par la source)
1 citation
Blood